Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | dna polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Entamoeba histolytica | deoxycytidyl transferase, putative | 0.0023 | 0.1847 | 0.5 |
Schistosoma mansoni | DNA polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase IV / kappa, putative | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Toxoplasma gondii | ImpB/MucB/SamB family protein | 0.0037 | 0.5597 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Giardia lamblia | DINP protein human, muc B family | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | unspecified product | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Echinococcus multilocularis | dna polymerase eta | 0.0052 | 0.9701 | 0.9633 |
Mycobacterium ulcerans | DNA polymerase IV | 0.0023 | 0.1847 | 0.5 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma brucei | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.9701 | 0.9633 |
Leishmania major | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0052 | 0.9701 | 1 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0053 | 1 | 1 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0053 | 1 | 1 |
Trypanosoma cruzi | DNA polymerase eta, putative | 0.0037 | 0.5597 | 0.4775 |
Mycobacterium tuberculosis | Possible DNA-damage-inducible protein P DinP (DNA polymerase V) (pol IV 2) (DNA nucleotidyltransferase (DNA-directed)) | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Mycobacterium tuberculosis | Conserved hypothetical protein | 0.0023 | 0.1847 | 0.5 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Leishmania major | DNA polymerase eta, putative | 0.0037 | 0.5597 | 0.4775 |
Trypanosoma brucei | DNA polymerase kappa, putative | 0.0023 | 0.1847 | 0.1904 |
Brugia malayi | ImpB/MucB/SamB family protein | 0.0052 | 0.9701 | 0.9633 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0053 | 1 | 1 |
Trypanosoma brucei | DNA polymerase IV, putative | 0.0023 | 0.1847 | 0.1904 |
Trichomonas vaginalis | DNA polymerase eta, putative | 0.0023 | 0.1847 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Inhibition (functional) | = 13 % | DNDI: Inhibition of Human African Trypanosomiasis, SBRI 427, in vitro at 2 ug.mL-1 | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.